LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

CEL-SCI Corp

Abierto

SectorSalud

0.22

Resumen

Variación precio

24h

Actual

Mínimo

0.21

Máximo

0.23

Métricas clave

By Trading Economics

Ingresos

-964K

-7.1M

BPA

-0.096

EBITDA

-225K

-5.9M

Dividendos

By Dow Jones

Próximas Ganancias

14 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-23M

21M

Apertura anterior

0.22

Cierre anterior

0.22

Noticias sobre sentimiento de mercado

By Acuity

86%

14%

367 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

CEL-SCI Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

15 may 2025, 22:52 UTC

Ganancias
Principales Movimientos del Mercado

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 may 2025, 20:37 UTC

Principales Noticias
Ganancias

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 may 2025, 00:00 UTC

Charlas de Mercado

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 may 2025, 23:47 UTC

Charlas de Mercado

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 may 2025, 23:38 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 may 2025, 23:38 UTC

Charlas de Mercado

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 may 2025, 23:14 UTC

Principales Noticias

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 may 2025, 22:46 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 may 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 may 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 may 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 may 2025, 21:58 UTC

Ganancias

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 may 2025, 21:24 UTC

Ganancias

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 may 2025, 20:56 UTC

Charlas de Mercado

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 may 2025, 20:54 UTC

Charlas de Mercado
Ganancias

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 may 2025, 20:54 UTC

Ganancias

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 may 2025, 20:51 UTC

Ganancias

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 may 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

15 may 2025, 20:50 UTC

Adquisiciones, fusiones, absorciones

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 may 2025, 20:50 UTC

Ganancias

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 may 2025, 20:47 UTC

Ganancias

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 may 2025, 20:37 UTC

Ganancias

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 may 2025, 20:26 UTC

Principales Noticias

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 may 2025, 20:25 UTC

Ganancias

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Comparación entre iguales

Cambio de precio

CEL-SCI Corp Esperado

Consenso

By TipRanks

0 ratings

0

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 0.2494Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

367 / 382 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CEL-SCI Corp

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.